Audit: QRS - Cannabidiol for Health & Longevity
Audit conducted on 22/09/2026 16:45 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 84 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All doses (15–50 mg, 150–300 mg), timings (2.5 weeks, 60–90 minutes, 2–4 weeks), thresholds (3× ULN, 2× ULN) and biomarker ranges trace to ER lines 397–419, 452, 480–492. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | hs-CRP row retains “which is unproven in humans”; time_3_sub retains “Where present, in the trials that found them”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Avoid-list populations stay in Contraindications; transplant immunosuppressants remain an absolute gate rather than a caution. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Every card draws from its own ER section; no Benefit- or Risk-Modifying Factor is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, author names, NCT identifiers or brand names anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, evidence-bounded register matching the ER Conclusion. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | States what is established, what conflicts, and what to measure, without hedging or alarm. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | No imperatives; protocol cells describe observed practice (“Split twice-daily dosing was used in every pivotal trial”). |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Descriptive throughout; only the template disclaimer addresses clinical decisions. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Cadence and protocol cells are stated as noun phrases, not recommendations. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns present in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to the Monitoring table and interaction gates where they are decision-bearing; ALT/AST are expanded in the table. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | All list items are key-fact fragments with no explanatory tails. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”/”your” anywhere. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Nine-marker monitoring panel and batch-verification gate assume a proactive, risk-aware reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Cadence requires repeated liver panels and daily home blood pressure. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content assumes access to laboratory testing and drug-level monitoring. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lede foregrounds the consumer-dose translation gap; qualitative_item_4 frames appetite loss as unwanted “at this stage of life”. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging” in the QRS. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Route of administration is given as “oral dose” / “Oil or softgel”; dosage forms named formally; no colloquial substitutes. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate headings, tier labels and table headers match the template byte-for-byte. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 named template spans present; the repeating marker_#/qualitative_item_# spans are instantiated as marker_1–9 and qualitative_item_1–6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Stylesheet, structure, website=”evidence_review”/”audit”/”full_review” spans and footer disclaimer are identical to the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Consumer oral protocol”, “Best time of day”, “Baseline biomarkers” and the interaction labels reproduce the ER bold labels; Monitoring row names match the ER biomarker column. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels are drawn from the ER’s own wording in Practical Considerations (“Acute calming”, “Blood-pressure reductions”, “Sleep and pain effects”). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji present; the ER’s “⚠️ Conflicted” markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is reduced to key-fact fragments; no explanatory prose, effect sizes or citations were carried over. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: cannabidiol_2026-0907-0235_Opus_ER.md at line 4. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.9.22, matching QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0922-1625. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word “Opus”. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” carries no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: cannabidiol_2026-0907-0235_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Confirmed across all nine keys. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Cannabidiol for Health & Longevity - Quick Reference Sheet” at line 22. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Cannabidiol for Health & Longevity” at line 417. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0922 rendered as 09/22/2026. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5” at line 425. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header matches the template exactly; the ER’s alternate-names line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “Cannabidiol is the non-intoxicating fraction of cannabis, sold as oils, capsules and creams for sleep, pain and stress” before any evidence verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses the Conclusion’s two established effects, the conflicted claims and the dominant harms. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 69 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Product forms and use cases from ER line 37; the two established effects, conflicted claims and harms from ER lines 525–527. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “around-the-clock blood pressure” replaces “24-hour ambulatory”, “raised blood levels of other medicines” replaces the interaction terminology. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years or sample sizes. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No mmHg figures, odds ratios or confidence intervals. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from the “Populations who should avoid Cannabidiol” list at ER lines 369–375. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven avoid-list populations are present, plus the transplant-immunosuppressant absolute contraindication from ER line 349. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s rationale tail “on the absence of human safety data rather than demonstrated harm” and the Child-Pugh gloss were stripped; no dash-led clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “three times the upper limit of normal”, “twice the upper limit of normal”, “Child-Pugh Class B or C” and “without transplant-clinic supervision” all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER identifies such populations and the section is correctly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eleven items map to ER bullets at lines 343–365. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Eleven of the ER’s twelve interaction bullets; transplant immunosuppressants correctly excluded because they sit in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eleven <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Severity words, consequences and mitigation sentences were all stripped; no dash-led clauses remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every named example drug list is preserved verbatim; only the purely definitional glosses (“CYP2C9 clears many drugs”, “CYP1A2 clears caffeine and several drugs”) were dropped as elaborations under 9.4. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies twelve such interactions and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells map to bullets in the ER Therapeutic Protocol section (lines 397, 411, 419). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing and pre-start safety testing — the three decisions a reader must make before and at first use. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine fields carry ER-derived content; no placeholders remain. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Exactly the three aspects named in the ER’s “Time to effect” bullet at line 452. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Blood pressure (High-tier benefit) leads, ahead of the two Low-tier benefits. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects exist and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine fields populated; time_1_sub also carries the steady-state note from ER line 409. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Every item corresponds to an ER Expected Benefits subheading. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER subheadings alone; no Magnitude paragraphs or mechanism text carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content in any benefits item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All thirteen items correspond to ER Potential Risks & Side Effects subheadings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Frequencies, odds ratios and mechanistic notes were all dropped; “THC” expanded to plain “tetrahydrocannabinol” as the ER prose does. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content in any risks item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows reproduce the ER Monitoring Protocol & Defining Success biomarker table (lines 482–492). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarkers present, with optimal ranges and rationales matching the ER table. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Baseline, 1/3/6-month and 6–12-month liver panel, blood-pressure and drug-level cadence taken from ER lines 480 and 492. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from the qualitative-marker list at ER lines 496–501. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six qualitative markers present and unabridged. |
Issues 22/09/2026 16:45
Pass rate 100.00%. No issues found.
Issues 22/09/2026 16:33
- 4.2 / 4.3 — Interaction label abbreviated: At line 599 the Key Interactions item reads “Sedating antihistamines (diphenhydramine, doxylamine) and alcohol”, abbreviating the ER’s bold label at ER line 357, “Over-the-counter sedating antihistamines (diphenhydramine, doxylamine) and alcohol:”; the dropped “Over-the-counter” narrows which antihistamines the interaction applies to.
Fixes 22/09/2026 16:33
- 4.2 / 4.3 — Interaction label restored verbatim: Changed the Key Interactions item from “Sedating antihistamines (diphenhydramine, doxylamine) and alcohol” to the ER’s bold label verbatim, “Over-the-counter sedating antihistamines (diphenhydramine, doxylamine) and alcohol”.
Issues 22/09/2026 16:30
- 4.2 / 4.3 — Protocol cell labels not ER-verbatim:
action_1_label(line 451) reads “Consumer Oral Dose” where the source bullet is labelled “Consumer oral protocol:” (ER line 397), andaction_2_label(line 465) reads “Timing”, which matches no ER bold label — the cell’s content comes from “Best time of day:” (ER line 407) and “Single versus split dosing:” (ER line 411).
Fixes 22/09/2026 16:30
- 4.2 / 4.3 — Protocol cell labels made ER-verbatim:
action_1_labelchanged from “Consumer Oral Dose” to the ER bullet label “Consumer oral protocol”,action_2_labelfrom the invented “Timing” to the ER bullet label “Best time of day”, andaction_3_labelfrom “Baseline Biomarkers” to the ER’s exact casing “Baseline biomarkers”.